Advarra signs TransPerfect as strategic language services provider

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/cybrain)
(Image: Getty/cybrain)
Advarra has selected TransPerfect Life Sciences as its strategic supplier of language services, including document translation, digital content localization, and interpretation services.

Advarra – formed recently following the merger of Chesapeake IRB and Schulman IRB​ – provides institutional review board (IRB), institutional biosafety committee (IBC), and global research compliance services.

TransPerfect has been a long-standing partner of both IRBs prior to the merger, Jeff Wendel, Advarra president told Outsourcing-Pharma.com.

"TransPerfect uses the translation memory we’ve built over years of working together to continuously improve translation turnaround times while maintaining high levels of accuracy and quality​," Wendel explained.

"Its TransPort platform provides our staff with transparency into the process, helping us to streamline our internal workflows to meet client timelines,​" he added.

TransPerfect also recently announced that ARCA Biopharma selected its Trial Interactive eTMF solution as its enterprise platform for clinical trials. 

The CO-based biopharmaceutical company used the solution to support a Phase II trial across 50 sites, and moving forward, will transfer all trials to a paperless environment.

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers